AI in Healthcare

Today's Stories

1. 1

   J&J wins FDA clearance for AI-powered bronchoscopy upgrade

   Johnson & Johnson received FDA clearance for MONARCH QUEST 3, a software update to its robotic-assisted bronchoscopy platform that adds AI-powered tools for procedure planning and lung nodule segmentation. The clearance expands J&J's footprint in minimally invasive diagnostics and robotic-assisted surgery, a growth area as the company faces patent expiration on older drugs. The update includes new digital ecosystem features designed to drive broader adoption of robotic and AI-guided tools in hospital and clinical settings.

   J&J is betting that MedTech platforms and robotic surgery can become a larger earnings engine alongside its core oncology and immunology drugs. Success hinges on converting AI-enabled tools like MONARCH QUEST 3 into meaningful procedure share and attractive margins while managing headwinds in orthopedics and potential tariff or litigation impacts.

2. 2

   AI drug discovery hinges on storage infrastructure, report says

   A report examines the foundational infrastructure needed to support AI-driven drug discovery, identifying storage as a critical component. As pharmaceutical companies adopt AI for drug development, the backbone systems that enable this work—particularly data storage and management—are becoming a strategic bottleneck that determines success or failure.

   The report signals that storage capacity and architecture decisions made now will shape which organizations can effectively scale AI drug discovery programs.

3. 3

   Apple researchers advance brain signal analysis with MVICAD2 technique

   Apple researchers introduced MVICAD2, a machine learning method that analyzes brain signals (magnetoencephalography data) from multiple subjects by accounting for both temporal delays and dilations in neural activity. The approach improves upon existing Multi-View Independent Component Analysis methods by allowing source signals to differ across subjects in timing and speed, validated using the Cam-CAN dataset and showing how these differences relate to aging. Brain imaging studies often assume identical neural sources across subjects, but individual variability—including age-related changes—makes this assumption unrealistic. MVICAD2 addresses this gap, potentially enabling more accurate group-level neuroscience analysis and better understanding of how brain dynamics vary with age, which could inform clinical and research applications.

   The research demonstrates superiority over existing multi-view independent component analysis methods in simulations; practical adoption will depend on how neuroscience labs and clinical researchers integrate the technique into their pipelines.

4. 4

   Whisker's $899 litter robot can't tell two cats apart

   The Litter-Robot 5 Pro, Whisker's premium model launched late last year, promises AI-powered cat facial recognition and health monitoring via a $8/month subscription, but after six months of testing, the system consistently failed to distinguish between two differently-looking cats, incorrectly assigned weight readings, and struggled to identify waste type. For cat owners considering a $899 device specifically for its AI health-monitoring claims, the core promise — early detection of health issues through accurate tracking — does not yet work; false data (like wrong weight assignments) can lead to false conclusions, and the reviewer had to manually correct visits and profiles to help the machine do its job.

   Whisker says the facial recognition system is built to learn and should improve over time, and the company has rolled out a new Patterns feature (summarizing each cat's daily visits and weight) several months after launch—but 5 Pro owners have been paying $8/month for features that did not work at release; the non-AI Litter-Robot 5 ($699) or LR4 ($699) may be better value.

5. 5

   J&J's Monarch lung robot gains FDA clearance for AI planning tools

   Johnson & Johnson announced Monday that its Monarch bronchoscopy robot received FDA clearance for a software update (Quest 3) that adds AI-powered pre-procedure planning, improved imaging system compatibility, and enhanced navigation and targeting capabilities. This is the platform's fourth major software launch in the past 18 months. Monarch is the first robotic bronchoscopy platform on the market and is used to assist physicians in lung biopsy procedures and early lung cancer diagnosis. The AI features are designed to automatically generate more accurate nodule boundaries during planning and improve visual orientation for physicians, potentially making procedures more precise and efficient.

   Monarch competes with Intuitive's Ion system and Noah Medical's Galaxy system in the bronchoscopy market. J&J also received FDA authorization last month for its Ottava soft tissue robotic system, which will compete against Intuitive's da Vinci robot and Medtronic's Hugo system.

6. 6

   Pharma Bets Billions on AI Drug Discovery Before Clinical Proof

   Pharmaceutical companies and investors are pouring billions into AI-driven drug discovery platforms—Isomorphic Labs raised $2.1 billion in May, while partnerships between Genesis Molecular AI and Incyte exceed $1 billion potential value, and Inceptive secured a deal with Alnylam worth up to $2 billion. These investments focus on end-to-end platforms and biological foundation models rather than individual drug assets. The industry is building general design engines (like Isomorphic's IsoDD platform) that can predict hidden protein binding sites and handle multiple drug modalities—expanding the range of diseases that can be tackled computationally. However, few AI-designed drugs have reached the clinic yet, raising questions about whether valuations are decoupled from clinical proof and depend instead on computational promise alone.

   Whether AI's generative design capabilities can actually accelerate drug approval timelines and reduce failure rates in clinical trials. One industry observer cautioned that even generatively designed molecules may take another seven years to reach patients, suggesting the most valuable innovation window exists now—before that first FDA approval.